Modus's Intended IPO to Spur Sickle Cell Drug R&D

With more advanced potential sickle cell therapies stumbling in the development process, the Stockholm, Sweden-based biotech Modus Therapeutics Holding AB has picked up the baton, saying it intends to raise extra financing through an initial public offering to support the further development of its Phase II potential sickle cell product, sevuparin.

Modus Therapeutics is the new name for Dilaforette Holding AB. Further details of the intended IPO are being worked out, including where and when to float, but a decision is...